While the VAT metabolic shifts induced by GLP-1, GIP and glucagon can be difficult to translate into a clinical perspective, data suggest that, although they act through different mechanisms, GLP-1, GIP and glucagon may contribute to restoring AT physiology in patients with obesity and insulin resistance. The gene discussed is GIP; the disease is obesity disorder.